Prescription Drug Cost Sharing – Associations With Medication and Medical Utilization and Spending and Health by Dana P. Goldman, PhD; Geoffrey F. Joyce, PhD; Yuhui Zheng, MPhil, JAMA. 2007;298:61-69. July 4, 2007
The Study
To study the relationship between cost-sharing and patient compliance, researchers reviewed 132 articles, published between 1985 and 2006 examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes.
Results, as excerpted from the abstract, show the following:
Commentary
There is little that is surprising in the findings. And, while the formula offered, For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient, may well oversimplify the connection between medication use and cost-sharing, it is a starting point for quantifying the economics of medication compliance and medication cost.

